Uniting Biotech & Pharma to Advance Beyond Atypical Antipsychotics & Transform Psychosis Treatment Across CNS Disorders
With the approval of Cobenfy as the first new schizophrenia drug of its kind, a resurgence of hope, commercial opportunity, and a regulatory path forward for new mechanisms beyond D2 agonism has reinvigorated the psychosis treatment landscape. At the same time, the inherent challenges of developing therapies for psychosis, underscored by setbacks of new candidates like Emraclidine, highlight the need for industry to unite, share experiences and learn from each other.Â
Our 2025 attendees left with actionnable insights on:
✓ Deciphering the underlying mechanisms of psychosis to uncover transformative new targetsÂ
✓ Discovering more translatable tools for predicting the antipsychotic efficacy of new drugsÂ
✓ Navigating biological and clinical heterogeneity of psychosis to innovate more targeted treatment approachesÂ
✓ Streamlining the regulatory path for new psychosis treatments with new mechanisms and new labelsÂ
Discovering Cutting-Edge Technologies
Exploring the latest innovations designed to drive advancements in discovery, translational and clinical development. Â
Connecting with Industry Leaders
Engaging directly with key stakeholders to explore solutions that address your R&D challenges and accelerate progress in your field.Â
Maximizing Networking Opportunities
Taking advantage of structured networking sessions to form new and meaningful connections with other industry players.Â
You Peers Joined in 2025 to:
Discover Breakthrough Therapies Beyond Atypical Antipsychotics with Ovid Therapeutics, Clexio Biosciences, Neumora and more.Â
Advance Innovative Preclinical Models to enhance translational validity and predict therapeutic efficacy more accurately.Â
Enhance Clinical Trial Success with Biomarker-Driven Patient Stratification & Personalized Medicine to optimize clinical trial outcomes and enhance regulatory approvals.Â
Explore New Strategies for Addressing Unmet Negative & Cognitive Symptom Domains. Â
Gain Insight into Regulatory & Commercial Implications of Emerging Psychosis Treatments.Â
Who Attended?
The Innovation in Psychosis Therapeutics Summit 2025 was your opportunity to collaborate with a specialized audience of 60+ experts in discovery, translational, and clinical development. It was the premier forum for advancing next-generation psychosis treatments across indications where your peers connected to exchange cutting-edge insights, forge strategic partnerships, and shape the future of psychosis therapeutics. Â
